Boston Scientific CORP Form 4 insider transactions

Director Cheryl Pegus reports acquisition of deferred stock units in Boston Scientific Corp.

Susan E. Morano, a director at Boston Scientific, reports the acquisition of common stock through equity awards.

Director Jessica L. Mega received an annual equity award and disposed of shares of Boston Scientific Corp. on May 8, 2025.

Director Edward J. Ludwig acquired 2,081 shares of Boston Scientific common stock as an annual equity award.

Director David C. Habiger of Boston Scientific Corp. received an annual equity award and disposed of shares on May 8, 2025.

Director Yoshiaki Fujimori of Boston Scientific Corp. received an annual equity award and disposed of shares on May 8, 2025.

John Bradley Sorenson, EVP of Global Operations at Boston Scientific, reports the vesting of restricted stock units and subsequent sale of shares under a pre-established trading plan.

Arthur Butcher, EVP & Group President at Boston Scientific, reports the acquisition and disposal of company stock and restricted stock units.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock on May 1, 2025, under a pre-established Rule 10b5-1 trading plan.

Arthur C. Butcher, EVP & Group President at Boston Scientific, reports the exercise of stock options and sale of shares under a pre-established 10b5-1 trading plan.

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, reports the sale of 4,826 shares of common stock at a price of $95.09 per share on April 21, 2025, under a pre-established Rule 10b5-1 trading plan.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock on April 1, 2025, under a pre-established Rule 10b5-1 trading plan.

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, sold 4,826 shares of common stock at a price of $100.85 on March 21, 2025, according to a Form 4 filing with the SEC.

Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, reports the acquisition and disposal of common stock and derivative securities, including transactions executed under a pre-established Rule 10b5-1 trading plan.

Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, executed stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Executive Vice President Joseph Michael Fitzgerald reports changes in beneficial ownership of Boston Scientific Corp stock, including gifts and indirect holdings.

Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Director Ellen M. Zane sold 13,586 shares of Boston Scientific (BSX) common stock at an average price of $104.2348 under a pre-established Rule 10b5-1 trading plan.

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, sold 4,826 shares of common stock at a price of $104.64 per share on February 21, 2025, according to a Form 4 filing.

Joseph Michael Fitzgerald, an EVP at Boston Scientific, reported a gift of 1,000 shares of common stock and disclaimed beneficial ownership of shares held by his child.

John Bradley Sorenson, EVP of Global Operations at Boston Scientific, sold shares of common stock on February 18 and 19, 2025, under a pre-established Rule 10b5-1 trading plan.

Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, sold 1,510 shares of common stock at $105.35 per share under a pre-established Rule 10b5-1 trading plan.

Daniel J. Brennan, EVP and CFO of Boston Scientific, reports multiple transactions involving the sale of common stock and the exercise of stock options, executed under a pre-established Rule 10b5-1 trading plan.

Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, reports transactions involving common stock and restricted stock units.

EVP of Global Operations at Boston Scientific, John Bradley Sorenson, reports multiple transactions involving common stock and derivative securities.

Miriam O'Sullivan, SVP, Chief HR Officer at Boston Scientific, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options.

Executive Vice President of Boston Scientific, Jeffrey Mirviss, reports acquisition and disposal of common stock and derivative securities.

Michael Mahoney, Chairman, President & CEO of Boston Scientific, reports acquisition and disposal of common stock and derivative securities.

Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific, reports multiple transactions involving common stock and restricted stock units.

Arthur C. Butcher, EVP & Group President at Boston Scientific, reports acquisition and disposal of common stock and derivative securities.